Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Neuromyelitis optica.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?

Pages